Lilly, Galapagos Put Some Trials On Hold Due To Coronavirus Concerns
Executive Summary
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.
You may also be interested in...
Pandemic Perspectives: R&D Lessons Learned From The COVID Year
The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.
Pharma R&D’s COVID-19 Scar
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.